Day One Biopharmaceuticals Inc [DAWN] stock is trading at $13.21, up 3.45%. An important factor to consider is whether the stock is rising or falling in short-term value. The DAWN shares have gain 7.92% over the last week, with a monthly amount glided 4.26%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Day One Biopharmaceuticals Inc [NASDAQ: DAWN] stock has seen the most recent analyst activity on October 09, 2024, when Needham reiterated its Buy rating and also boosted its price target to $33 from $32. Previously, BofA Securities upgraded its rating to Buy on August 01, 2024, and elevated its price target to $24. On April 24, 2024, Needham reiterated its Buy rating and revised its price target to $33 on the stock. BofA Securities downgraded its rating to a Underperform and decreased its price target to $9 on April 25, 2023. CapitalOne initiated its recommendation with a Overweight and recommended $40 as its price target on February 08, 2023. In a note dated December 15, 2022, H.C. Wainwright initiated an Buy rating and provided a target price of $35 on this stock.
Day One Biopharmaceuticals Inc [DAWN] stock has fluctuated between $11.13 and $18.07 over the past year. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Day One Biopharmaceuticals Inc [NASDAQ: DAWN] shares were valued at $13.21 at the most recent close of the market. An investor can expect a potential return of 81.68% based on the average DAWN price forecast.
Analyzing the DAWN fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -2.06%, Pretax Profit Margin comes in at -0.82%, and Net Profit Margin reading is -0.82%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.22 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.67 points at the first support level, and at 12.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.64, and for the 2nd resistance point, it is at 14.07.
Ratios To Look Out For
For context, Day One Biopharmaceuticals Inc’s Current Ratio is 14.62. On the other hand, the Quick Ratio is 14.55, and the Cash Ratio is 10.64. Considering the valuation of this stock, the price to sales ratio is 13.07, the price to book ratio is 2.40.
Transactions by insiders
Recent insider trading involved Blackman Samuel C., HEAD OF R&D, that happened on Dec 10 ’24 when 30000.0 shares were sold. CHIEF EXECUTIVE OFFICER, Bender Jeremy completed a deal on Nov 18 ’24 to sell 10554.0 shares. Meanwhile, HEAD OF R&D Blackman Samuel C. sold 2206.0 shares on Nov 18 ’24.
